Healthcare Bioconvergence Market Size Estimated to Reach USD 259.55 Bn by 2032 [Yahoo! Finance]
Century Therapeutics, Inc. (IPSC)
Company Research
Source: Yahoo! Finance
Ottawa, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global healthcare bioconvergence market size accounted for USD 130.49 billion in 2023, and grew to USD 140.85 billion in 2024, According to Precedence Research. Europe region dominated the market with the largest market share of 30% in 2022. Bioconvergence is a specialized healthcare and life science research area that combines engineering/technology with computerized systems. It acknowledges that biology and technology, the two main aspects of biotechnology, can work together effectively. This approach recognizes that biological processes and technological innovations can collaborate and advance biotechnology The Full Study is Readily Available | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/2962 Bioconvergence is a well-established strategy in Israel and the United States, proving to be an asset for progress in life sciences and the healthcare sector. Its application is anticipated to enhance
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewswire
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $9.00 price target on the stock, down previously from $10.00.MarketBeat
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsGlobeNewswire
IPSC
Earnings
- 11/9/23 - Miss
IPSC
Analyst Actions
- 3/15/24 - Canaccord Genuity
IPSC
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- IPSC's page on the SEC website